9,27 Although the number of patients who had received prior adjuvant or neoadjuvant chemotherapy with trastuzumab was small, the progression-free survival benefit of pertuzumab plus trastuzumab ...

9 Dual HER2 blockade with pertuzumab and trastuzumab is the standard of care as first-line therapy for patients with advanced HER2-positive disease. As part of a neoadjuvant regimen, pertuzumab ...

The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.

NEW ORLEANS — Results from the I-SPY 2 trial show that a new presurgery (neoadjuvant) combination of trastuzumab emtansine (T-DM1; Kadcyla, Genentech, Inc) and pertuzumab (Perjeta, Genentech ...

The term neoadjuvant means that a person typically ... A doctor may recommend both pertuzumab and trastuzumab if a person has a higher risk of recurrent breast cancer or metastases in the lymph ...

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open ...

For safety, 23% and 33% of adverse events (AEs) were associated with pertuzumab (Perjeta ... of TILs after either SC or intravenous neoadjuvant trastuzumab,” the study authors wrote.

in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and ...